Rheumatoid arthritis New treatments, better outcomes

Nurse Practitioner

Volumn 37, Issue 11, 2012, Pages 16-22

  Salt, Elizabeth ^a   Crofford, Leslie ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biologic medications; Chronic autoimmune disease; Evidence based management of rheumatoid arthritis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICLE; EVIDENCE BASED PRACTICE; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; EVIDENCE-BASED PRACTICE; HUMANS; TREATMENT OUTCOME;

EID: 84868574574     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000421427.01505.0e     Document Type: Article

References (39)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002;46(2):328-346.
2. American College of Rheumatology. Prevalence Statistics.http://www. rheumatology.org/practice/clinical/patients/diseases-and-conditions/ra.asp.
3. Center for Disease Control. Data and Statistics: National Statistics, epidemiology briefs, rheumatoid arthritis.http://www.cdc.gov/arthritis/data- statistics/epi-briefs/rheumatoid.htm.
4. Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010; 62:1576-1582.
5. Gonzalez A, Kremers HM, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583-3587.
6. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77-90.
7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62(9):2569-2581.
8. Cader MZ, Filer A, Hazlehurst J, de Pablo P, Buckley CD, Raza K. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: Comparison with 1987 ACR Criteria in a very early synovitis cohort. Ann Rheum Dis. 2010; 70(6):949-955.
9. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62(12):3537-3546.
10. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573-586.
11. Finckh A, Bansback N, Marra CA, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: A cost-effectiveness analysis. Ann Intern Med. 2009;151(9): 612-621.
12. U.S. Food and Drug Administration. Database of FDA approved drugs.http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
13. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: Recommendation of an international task force. Ann Rheum Dis. 2010;69(4):631-637.
14. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-784.
15. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
16. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. 2003. Rheumatoid Arthritis.http://www. fda.gov/ohrms/dockets/ac/03/briefing/3930B2-02-D-Sec1-Tab3.htm.
17. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial. Lancet. 2004;363:675-681.
18. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial. Ann Rheum Dis. 2011;70(1): 39-46.
19. American College of Rheumatology. Anti-TNF.http://www.rheumatology.org/ practice/clinical/patients/medications/anti-tnf.asp.
20. Feldmann M, Maini RN. Anti-TNF alpha therapy of RA: What we have learned. Annu Rev Immunol. 2001;19:163-196.
21. Abbott. Humira-Full Prescribing Information.http://www.rxabbott.com/pdf/ humira.pdf.
22. Amgen. Enbrel-Full Prescribing Information.http://pi.amgen.com/united- states/enbrel/derm/enbrel-pi.pdf
23. Radstake DJ, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11): 1739-1745.
24. Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab Pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3319-3329.
25. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human antitumor necrosis factor -monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272-2283.
26. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New Engl J Med. 2005;353(11):1114-1123.
27. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-997.
28. Cohen M. American College of Rheumatology Hotline: Abatacept and Rituximab.http://rheumatology.org/publications/hotline/0506newdrugs.org.
29. Janssen. Simponi-Full prescribing information.http://www.simponi.com/hcp/ sites/default/files/hcp-files/pdf/prescribing-information.pdf.
30. UCB. Cimzia: Full Prescribing Information.http://www.cimzia.com/ rheumatoidarthritis/hcp/pdf/Prescribing-Information.pdf.
31. Bristel-Myers Squibb. Orencia Full prescribing information.http://www. orencia.com/index.aspx.
32. Genentech. Rituxan-Full prescribing information.http://www.gene.com/gene/ products/information/pdf/rituxan-prescribing.pdf.
33. Genentech. Actemra-Full prescribing information.http://www.gene.com/gene/ products/information/actemra/pdf/pi.pdf.
34. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: An open-label randomized controlled trial. J Rheumatol. 2011;38(10):2169-2171.
35. Clinicalttrials.gov. Phase III Rheumatoid arthritis and biologics and interventional studies.http://clinicaltrials.gov/ct2/show/.
36. American College of Rheumatology. Tocilizumab.http://www.rheumatology. org/practice/clinical/patients/medications/tocilizumab.asp.
37. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
38. Janssen. Remicade-Full prescribing information.http://www.remicade.com/ hcp/remicade/assets/hcp-ppi.pdf.
39. Tesser RP. Hotline: Tocilizumab for the treatment of rheumatoid arthritis.http://www.rheumatology.org/publications/hotline/2010-02-03- tocilizumab.asp.